Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. USO
4. KBH
5. HTZ
6. QCOM
7. SPY
8. HON
9. SPCX
10. TTWO

Go back to Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

Agios Pharma (AGIO) Posts Smaller-than-Expected Q1 Loss

May 7, 2015 8:00 AM EDT

Agios Pharma (NASDAQ: AGIO) reported Q1 EPS of ($0.13), $0.79 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $34.2 million versus the consensus estimate of $10.86 million.

Cash, cash equivalents and marketable securities as of March 31, 2015 were $440.0 million, compared to $467.4 million as of December 31, 2014. The... More